Abstract
The FDA has issued a safety alert about potential cardiotoxicity of imatinib mesylate (Gleevec), a drug used to treat chronic myeloid leukemia and gastrointestinal stromal tumors. In a new warning added to the drug label, the manufacturer notes that Gleevec users with heart disease or at risk for heart failure (HF) should be monitored carefully and that users who …
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
